December 2025

VZV Clinical Trial Phase Ⅱ

Rhegen Biotech officially initiates Phase Ⅱ clinical trial for its lyophilized VZV mRNA vaccine.

November 2025

TB Approval Obtained

Rhegen Biotech receives CDE approval for clinical trial application of its lyophilized TB mRNA vaccine.

October 2025

PCV Project Clinical Launch

Rhegen Biotech officially initiates Phase I clinical trial for its personalized cancer mRNA vaccine.

May 2025

VZV Project Clinical Launch

Rhegen Biotech officially initiates Phase I clinical trial for its lyophilized herpes zoster mRNA vaccine.

March 2025

RSV Approval Obtained

Rhegen Biotech receives CDE approval for clinical trial application of its lyophilized bivalent respiratory syncytial virus mRNA vaccine.

January 2025

Cap2 Patent Filed

Rhegen Biotech completes DMF filing with U.S. FDA for its proprietary cap analog.

December 2024

RHT19 Patent Filed

Rhegen Biotech completes DMF filing from both U.S. FDA and China CDE for its proprietary cationic lipid as a pharmaceutical excipient.

October 2024

VZV Approval Obtained

Rhegen Biotech receives CDE approval for clinical trial application of the world's first lyophilized herpes zoster mRNA vaccine.

July 2024

ISO Certification

Rhegen Biotech and its subsidiary (Wuhan Rhegen Biotechnology Co., Ltd.) successfully obtained ISO's three major system certificates, setting a new benchmark in the mRNA industry.

December 2022

Qualification Accreditation

Rhegen Biotech is qualified as a National High-tech Enterprise.

November 2022

COVID-19 Vaccine Approved

Rhegen Biotech obtains clinical approval in Hong Kong and New Zealand for its lyophilized Omicron variant mRNA vaccine against COVID-19.

May 2021

Angel Round Investment

Rhegen Biotech obtained an angel investment round.

September 2019

Company Establishment

Shenzhen Rhegen Biotechnology Co., Ltd. is established.